1. Home
  2. ANL vs PAR Comparison

ANL vs PAR Comparison

Compare ANL & PAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.20

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Logo PAR Technology Corporation

PAR

PAR Technology Corporation

HOLD

Current Price

$14.36

Market Cap

640.6M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
PAR
Founded
2004
1968
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
731.6M
640.6M
IPO Year
2022
1995

Fundamental Metrics

Financial Performance
Metric
ANL
PAR
Price
$10.20
$14.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$20.00
$33.20
AVG Volume (30 Days)
129.2K
1.3M
Earning Date
04-10-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$455,547,000.00
Revenue This Year
$36.02
$9.82
Revenue Next Year
N/A
$11.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.16
52 Week Low
$0.88
$11.59
52 Week High
$17.25
$72.15

Technical Indicators

Market Signals
Indicator
ANL
PAR
Relative Strength Index (RSI) 40.94 48.11
Support Level $6.92 $13.85
Resistance Level $12.59 $15.10
Average True Range (ATR) 1.15 0.92
MACD -0.11 -0.15
Stochastic Oscillator 26.07 32.01

Price Performance

Historical Comparison
ANL
PAR

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About PAR PAR Technology Corporation

PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.

Share on Social Networks: